share_log

CareDx Expects Q4 Revenue Of $85M-$86M Vs $82.16M Est, FY24 Revenue Of $332M-$333M Vs $329.4M Est, FY25 Revenue Of $370M Vs $366.7M Est

CareDx Expects Q4 Revenue Of $85M-$86M Vs $82.16M Est, FY24 Revenue Of $332M-$333M Vs $329.4M Est, FY25 Revenue Of $370M Vs $366.7M Est

CareDx預計第四季度營業收入爲8500萬到8600萬,預期爲8216萬;2024財年的營業收入爲33200萬到33300萬,預期爲32940萬;2025財年的營業收入爲37000萬,預期爲36670萬。
Benzinga ·  01/13 12:06

CareDx, Inc. (NASDAQ:CDNA) – The Transplant Company – today reported preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2024.

CareDx公司(納斯達克:CDNA)——移植公司——今天報告了截至2024年12月31日的第四季度和全年初步未經審計的財務結果。

Preliminary Fourth Quarter 2024 Financial Results

2024年第四季度初步財務結果

  • Revenue is expected to be between $85 million and $86 million, an increase of approximately 30% year-over-year.
  • Testing services revenue is expected to be between $62.5 million and $63.5 million, an increase of approximately 35% year-over-year.
  • Testing Services volume of approximately 45,500 increased 14% year-over-year.
  • Revenue is expected to be $11.4 million for Digital Solutions and $11.4 million for Products.
  • GAAP loss is expected to be approximately $32 million to $34 million and adjusted EBITDA is expected to be a gain of between $8 million and $9 million.
  • 營業收入預計在8500萬到8600萬之間,同比增長約30%。
  • 檢測服務營業收入預計在6250萬到6350萬之間,同比增長約35%。
  • 檢測服務成交量約爲45,500,同比增長14%。
  • 數字解決方案的營業收入預計爲1140萬,產品的營業收入預計爲1140萬。
  • 根據普遍會計準則(GAAP)預期虧損約爲3200萬到3400萬,調整後的EBITDA預期爲800萬到900萬的收益。

Preliminary Full Year 2024 Financial Results

2024年全年初步財務結果

  • 2024 revenue is expected to be between $332 million to $333 million.
  • 2024 GAAP loss is expected to be between $58 million and $60 million and adjusted EBITDA is expected to be a gain of between $25 million to $26 million.
  • Cash, cash equivalents, and marketable securities as of December 31, 2024, is expected to be approximately $261 million, an increase of approximately $26 million year-over-year.
  • 2024年的營業收入預計在33200萬元到33300萬元之間。
  • 2024年的GAAP損失預計在5800萬元到6000萬元之間,調整後的EBITDA預計將獲得2500萬元到2600萬元的收益。
  • 截至2024年12月31日,現金、現金等價物和可交易證券預計約爲26100萬元,同比增長約2600萬元。

2025 Revenue Guidance

2025年營業收入指引

  • CareDx anticipates revenue of $370 million during 2025.
  • CareDx預計2025年的營業收入爲37000萬元。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
評論 評論 · 瀏覽 222

熱點推薦

搶先評論

聲明

本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。